{
  "actions": [
    {
      "acted_at": "2019-02-06", 
      "action_code": "Intro-H", 
      "references": [], 
      "text": "Introduced in House", 
      "type": "action"
    }, 
    {
      "acted_at": "2019-02-06", 
      "action_code": "H11100", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2019-02-06", 
      "action_code": "H11100", 
      "committees": [
        "HSBA"
      ], 
      "references": [], 
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr990-116", 
  "bill_type": "hr", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Financial Services", 
      "committee_id": "HSBA"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }
  ], 
  "congress": "116", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2019-02-06", 
  "number": "990", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "s344-116", 
      "identified_by": "CRS", 
      "reason": "identical", 
      "type": "bill"
    }
  ], 
  "short_title": "Hatch-Waxman Integrity Act of 2019", 
  "sponsor": {
    "bioguide_id": "F000461", 
    "district": "17", 
    "name": "Flores, Bill", 
    "state": "TX", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2019-02-06", 
  "subjects": [
    "Administrative remedies", 
    "Drug safety, medical device, and laboratory regulation", 
    "Fraud offenses and financial crimes", 
    "Health", 
    "Intellectual property", 
    "Licensing and registrations", 
    "Prescription drugs", 
    "Securities"
  ], 
  "subjects_top_term": "Health", 
  "summary": null, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Hatch-Waxman Integrity Act of 2019", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Hatch-Waxman Integrity Act of 2019", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Hatch-Waxman Integrity Act of 2019", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-07-30T13:16:27Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr/BILLSTATUS-116hr990.xml"
}